Amoy Diagnostics Co Ltd (300685) - Total Assets
Based on the latest financial reports, Amoy Diagnostics Co Ltd (300685) holds total assets worth CN¥2.25 Billion CNY (≈ $328.69 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See what is Amoy Diagnostics Co Ltd's book value for net asset value and shareholders' equity analysis.
Amoy Diagnostics Co Ltd - Total Assets Trend (2012–2024)
This chart illustrates how Amoy Diagnostics Co Ltd's total assets have evolved over time, based on quarterly financial data.
Amoy Diagnostics Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Amoy Diagnostics Co Ltd's total assets of CN¥2.25 Billion consist of 86.6% current assets and 13.4% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 40.1% |
| Accounts Receivable | CN¥545.65 Million | 26.4% |
| Inventory | CN¥34.37 Million | 1.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥43.58 Million | 2.1% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2012–2024)
This chart illustrates how Amoy Diagnostics Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Amoy Diagnostics Co Ltd (300685) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Amoy Diagnostics Co Ltd's current assets represent 86.6% of total assets in 2024, an increase from 49.7% in 2012.
- Cash Position: Cash and equivalents constituted 40.1% of total assets in 2024, up from 21.9% in 2012.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 24.0% in 2012.
- Asset Diversification: The largest asset category is accounts receivable at 26.4% of total assets.
Amoy Diagnostics Co Ltd Competitors by Total Assets
Key competitors of Amoy Diagnostics Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Dr. Lal Path Labs Ltd.
NSE:LALPATHLAB
|
India | Rs29.59 Billion |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
China | CN¥984.94 Million |
|
Diagnos Laboratorium Utama PT Tbk
JK:DGNS
|
Indonesia | Rp304.08 Billion |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$17.03 Billion |
|
Integral Diagnostics Ltd
AU:IDX
|
Australia | AU$1.43 Billion |
|
Australian Clinical Labs Ltd
AU:ACL
|
Australia | AU$562.50 Million |
|
Healius Ltd
AU:HLS
|
Australia | AU$1.77 Billion |
|
Monash Ivf Group Ltd
AU:MVF
|
Australia | AU$510.21 Million |
Amoy Diagnostics Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.92 | 8.06 | 6.74 |
| Quick Ratio | 10.69 | 7.89 | 6.59 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.81 Billion | CN¥1.53 Billion | CN¥859.03 Million |
Amoy Diagnostics Co Ltd - Advanced Valuation Insights
This section examines the relationship between Amoy Diagnostics Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.01 |
| Latest Market Cap to Assets Ratio | 0.56 |
| Asset Growth Rate (YoY) | 6.7% |
| Total Assets | CN¥2.06 Billion |
| Market Capitalization | $1.16 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Amoy Diagnostics Co Ltd's assets below their book value (0.56x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Amoy Diagnostics Co Ltd's assets grew by 6.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Amoy Diagnostics Co Ltd (2012–2024)
The table below shows the annual total assets of Amoy Diagnostics Co Ltd from 2012 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥2.06 Billion ≈ $302.15 Million |
+6.71% |
| 2023-12-31 | CN¥1.93 Billion ≈ $283.13 Million |
+17.20% |
| 2022-12-31 | CN¥1.65 Billion ≈ $241.58 Million |
+8.62% |
| 2021-12-31 | CN¥1.52 Billion ≈ $222.41 Million |
+17.56% |
| 2020-12-31 | CN¥1.29 Billion ≈ $189.19 Million |
+23.51% |
| 2019-12-31 | CN¥1.05 Billion ≈ $153.18 Million |
+27.85% |
| 2018-12-31 | CN¥818.75 Million ≈ $119.81 Million |
+17.83% |
| 2017-12-31 | CN¥694.85 Million ≈ $101.68 Million |
+96.67% |
| 2016-12-31 | CN¥353.30 Million ≈ $51.70 Million |
+16.81% |
| 2015-12-31 | CN¥302.45 Million ≈ $44.26 Million |
+71.42% |
| 2014-12-31 | CN¥176.44 Million ≈ $25.82 Million |
+59.89% |
| 2013-12-31 | CN¥110.35 Million ≈ $16.15 Million |
+65.07% |
| 2012-12-31 | CN¥66.85 Million ≈ $9.78 Million |
-- |
About Amoy Diagnostics Co Ltd
Amoy Diagnostics Co., Ltd. engages in research and development, production, sale, and supporting services of tumor precision medical diagnostic products in China and internationally. The company offers AmoyDx homologous recombination deficiency (HRD) focus panel solutions, evaluates PARP inhibitor-related biomarkers and advances targeted treatment research in ovarian cancer; AmoyDx comprehensive … Read more